Fig. S1. Forest plot showing the overall result in psoriasis patients with: (a) age at entry, (b) age at diagnosis, (c) Dermatology Quality of Life Index (DLQI), (d) Psoriasis Area Severity Index (PASI), (e) body surface area affected (BSA) and the odds ratio (OR) of biologic use compared with conventional treatment among (f) male patients, (g) patients with psoriatic arthritis, (h) patients with psoriasis different from chronic plaque psoriasis, and (i) with nail disease.

The main differences are found between biologic and conventional treatment groups of psoriasis in: (a) age at entry, (b) age at diagnosis, (c) Dermatology Quality of Life Index (DLQI), (d) Psoriasis Area Severity Index (PASI), (e) body surface area affected (BSA) and the odds ratio (OR) of biologic use compared with conventional treatment among (f) male patients, (g) patients with psoriatic arthritis, (h) patients with psoriasis different from chronic plaque psoriasis, and (i) with nail disease.